Sphingolipid, ceramide has been reported to initiate Nlrp3 inflammasome formation and activation in different pathological conditions including insulin resistance, obesity, Alzheimer's disease, cystic fibrosis and acute lung injury [6, 7]. The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.